Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 85Neoplasm Metastasis 74Colorectal Neoplasms 74Neoplasms 72Leukemia, Myeloid, Acute 62Breast Neoplasms 54Prostatic Neoplasms 47Multiple Myeloma 47Ovarian Neoplasms 42Pancreatic Neoplasms 41Squamous Cell Carcinoma of Head and Neck 38Melanoma 36Recurrence 33Glioblastoma 33Lung Neoplasms 31Myelodysplastic Syndromes 30Triple Negative Breast Neoplasms 29Lymphoma, Non-Hodgkin 29Advanced Solid Tumors 27Endometrial Neoplasms 26Stomach Neoplasms 24Small Cell Lung Carcinoma 24Carcinoma, Renal Cell 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Brain Neoplasms 22Carcinoma, Hepatocellular 21Sarcoma 19Lymphoma, B-Cell 19Lymphoma, Large B-Cell, Diffuse 18Esophageal Neoplasms 18

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Congenital Bone Marrow Failure Syndromes × 30 days × Clear all
NCT06090669 2026-06-03

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
75 enrolled
Classical hematology

Congenital Bone Marrow Failure Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡